Evidence map›Paper›PMID 29174379›Full record

ArticleClinics and research in hepatology and gastroenterology2018

A new pathway to eSCAPe lipotoxicity.

Fadila Benhamed, Catherine Postic

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinics and research in hepatology and gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Fadila BenhamedInserm, U1016, institut Cochin, 75014 Paris, France; CNRS-UMR8104, 75014 Paris, France; Université Paris-Descartes, Sorbonne-Paris-Cité, 75005 Paris, France.
Catherine PosticInserm, U1016, institut Cochin, 75014 Paris, France; CNRS-UMR8104, 75014 Paris, France; Université Paris-Descartes, Sorbonne-Paris-Cité, 75005 Paris, France. Electronic address: catherine.postic@inserm.fr.
Institut Cochin · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular mechanisms underlying fatty liver progression towards more severe syndromes are complex and only partially understood. Studies have recently reported that lipotoxic fatty acid metabolites are instrumental in the development of hepatocyte injury in the context of fatty liver disease. The recent study by Papazyan et al. published in Cell Metabolism (2016;24(6):863-874) addresses this issue and reveals that rescuing de novo fatty acid synthesis (lipogenesis) through the activation of the transcription factor SREBP-1c can prevent lethality as well as severe lipotoxicity caused by a combined deficiency in lipogenesis and β-oxidation. Altogether, this study reveals that optimizing lipid signals generated by lipogenesis through SREBP-1c can help redirect fatty acids toward beneficial actions, by buffering lipotoxic lipid intermediates even in the setting of lipid overload.

Indexed as

LipogenesisSterol Regulatory Element Binding Protein 1Fatty AcidsFatty LiverHepatocytesHumansLiverFatty AcidsSterol Regulatory Element Binding Protein 1De novo lipogenesisLipotoxicity;NAFLDSREBP-1c

Identifiers

PMID29174379
OpenAlexW2770114531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.